Sign inJoin waitlistJoin the waitlist

Elizabeth Budde

Executive Medical Director, Enterprise Immune Effector Cell Program · City of Hope National Medical Center

Credentials: · · · ·

History

Enterprise Immune Effector Cell Program · City of Hope National Medical Center
Present
City of Hope National Medical Center
Present

Hematology and Medical Oncology
1998–2001
Internal Medicine
1995–1998
Doctor of Medicine
1991–1995

Research

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Molecular Therapy · 2017 · 517 citations
Management of Immunotherapy-Related Toxicities, Version 1.2019
Journal of the National Comprehensive Cancer Network · 2019 · 447 citations
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Blood · 2012 · 443 citations

Stephen Forman
47 papers
MM
Matthew Mei
29 papers
AH
Alex Herrera
28 papers
Leslie Popplewell
23 papers
LK
Larry Kwak
19 papers
Nancy Bartlett
16 papers
TS
Tanya Siddiqi
15 papers
Ibrahim Aldoss
14 papers
Geoffrey Shouse
13 papers
Steven Rosen
13 papers
Ahmed Aribi
12 papers
Guido Marcucci
12 papers

Grants

Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute · R01
PI · $2.4M · Beckman Research Institute/City of Hope
2021–2026

Clinical trials

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
Principal investigator · Withdrawn · Phase 1
City of Hope Medical Center
2021–2024
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Recruiting · Phase 2
City of Hope Medical Center
2020–2026
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Principal investigator · Terminated · Phase 1, Phase 2
Mustang Bio
2020–2023
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
Principal investigator · Active not recruiting · Phase 1, Phase 2
City of Hope Medical Center
2019–2025